In order to enhance the therapeutic efficacy of azidothymidine (AZT) by improving its pharmacoktnetlc properties, three prodrugs of AZTwere synthesized by esterifying the 5'-hydroxyl of AZT with three pharmacologically inactive steroidal 1713-carboxylic acids. Preliminary results of in vitro anti-HIV activity screening of the compounds show that~IJ' of these esters have anti-HIV activity comparable to that of AZT. This report discusses the synthesis and anti-HIV activity screening results of the prodrugs. . *For correspondence. Tel. 904 599 3638. Fax. 904 599 3952.
Introduction
Azidothymidine (AZT) is a potent inhibitor of HIV replication and the first clinically successful drug for AIDS and AIDS related symptoms (Yarchoan et aI., 1986) . However, AZT chemotherapy causes dose-related bone marrow toxicity manifested as severe anaemia and leucopaenia (Richman, 1987) . Pharmacokinetic studies in humans have shown that its plasma half life is approximately 1 h (Klecker et el., 1987) and its major metabolite, excreted in urine, is 5 '-O-glucuronidate (De Clercq, 1987) . The short plasma half life which is mainly ascribed to 5 '-O-glucuronidation resulting in rapid elimination of AZT ensures administration higher dosages for maintaining adequate therapeutic drug levels in plasma. However, that leads to bone marrow toxicity. Therefore it is reasoned that 5 '-0conjugates of AZT in prodrug forms may significantly overcome the drawbacks of AZT and improve its efficacy. Successful prodrugs are expected to possess good stability in plasma, and yet generate therapeutically effective levels of AZT in the target tissues.
Recently, several research groups have reported synthesis of different types of conjugates of AZT with amino acids, heterocyclic acids, retinoic acid (Aggarwal et al., 1990; McGuigan et al., 1990) , sugars (Henin et al., 1991) and lipids (Piantadosi et al., 1991) . In these prodrugs, conjugating moiety is linked to AZT through a 5 '-O-ester or 5 '-O-phosphate group. The 5 '-O-esters of AZT have been designed to improve their pharmacokinetic profile and enhance their uptake in the target tissues. The prodrugs with phosphate linkage have been designed to deliver AZT as its monophosphate, thereby overcoming the problem of poor monophosphorylation.ln comparison to AZT, some of the prod rugs show similar anti-HIV activity with much improved pharmacokinetic properties such as increased plasma half life, Iipophilicity and cell uptake, and decreased toxicity. These results clearly demonstrate the encouraging potential of a prod rug approach in improving the therapeutic profile of AZT.
With this in mind, we have synthesized three 5'-0esters of AZT with three different pharmacologically inactive steroidal 1713-carboxylic acids. Since the steroidal acids chosen retain some of the glucocorticoid structural features such as 3-keto, 4-ene and 11-hydroxy groups, the conjugates are expected to bind to transcortins, the plasma glucocorticoid transport proteins. The conjugate-protein complex would be protected from metabolic transformation in plasma, thus prolonging the half life of the nucleoside.
Results

Chemistry
Steroidal acid 1 ( Fig. 1 ) was synthesized by oxidative cleavage of the 1713-side chain of corticosterone with periodic acid (Kertesz and Marx, 1986) . Similarly, acid 3 ( Fig. 1 ) was obtained from prednisolone using K 2C03 and air (Kertesz and Marx, 1986) . Methyl ester of acid 2 was synthesised according to the previously described procedure (Taraporewala et al., 1989) and then the ester was hydrolysed with NaOH/MeOH to afford acid 2. All the three acids were obtained in good yield and characterized by IR, 1H NMR and elemental analysis.
5'-O-esters 4 and 5 were prepared (Fig. 2 ) by condensing AZT with steroidal acids 1 and 2 in the presence of dicyclohexylcarbodiimide (DCC)and 4-dimethylaminopyridine (DMAP) in 85% and 80% yield, respectively. For the synthesis of ester 6 ( Fig. 2) , acid 3 was first activated with carbonyldiimidazole (CDI) to afford the reactive intermediate, acid imidazolate. The reaction of theimidazolate with AZT in the presence of DMAP then afforded ester 6 in 74% In order to ensure that the conjugates remain stable in cell culture medium, their stability was also investigated. All were incubated under identical physical condition for six days. The incubation mixture was analysed by HPLC both immediately before and after the incubation. No free AZT was detected at the highest sensitivity (0.001 aufs) of a UV detector at 267nm wave length. HPLC profile of esters and AZT is shown in Table 2 . The experiment clearly shows that esters remain stable under the conditions of the anti-HIV activity screening protocol. It also indicates that the conjugates enter T4 cells intact and then act as an anti-HIV agent.
Discussion
Three prodrugs of the anti-HIV AZT have been synthesized as 5' -O-esters of AZT and 17f3-steroidal acids. These prodrugs have been found to exhibit anti-HIV activity and cell toxicity comparable to those of AZT. Moreover, they
• Tested in T 4 lymphocytes (CEM cell line); after incubation, cell viability was determined microscopically and by tetrazolium salt procedure. t Average of 4 assays. IC 5 0 : inhibitory concentration, concentration of test compound required to inhibit 50% cell growth compared to control. EC50: effective concentration, concentration of test compound required to protect 50% cells from HIV-I induced cell death compared to control. The IC50 and EC50 values obtained for AZT from the National Cancer Institute are 1.0 x 10-6 and 1.1 -0.13 x 10-8 respectively.
*TI: therapeutic index.
1.53 X 10-7 9.65 X 10-8 1.07 X 10-6 2.39 X 10-5 >5.95 X 10~5 2.30 X 10-5
yield. For all the esters, satisfactory 1 H NMR, IR and elemental analyses data were obtained confirming the formation of 5' -O-esters of AZT with steroidal acids.
Anti-HIVactivity
All the esters were tested for their in vitro anti-HIV activity at the National Cancer Institute. Briefly, HIV-1 and a solution of conjugates (in Me2S0 and cell culture medium) were added to Ta-lymphocytes (CEM cell line). The resultant mixture was incubated for 6 days in 5% CO 2 atmosphere at 37°C. Cell viability was then determined both microscopically and by using tetrazolium (XTT) salt procedure. Toxic controls were also used to evaluate toxicity of the conjugates. As shown in Table 1 , all conjugates are active as anti-HIV agents and show activity (EC so ) and toxicity (IC so ) comparable to those of AZT. Among all three conjugates, 6 is slightly less active than both 4 and 5, which have similar activity. All of them show similar toxicity. 170', 11{3-Dihydroxy-3-oxoandrosta-1,4-diene-17{3carboxylic acid (3) have also been found stable in a cell culture medium.
Since the steroidal moieties of the conjugates are expected to protect the conjugates from rapid biotransformation in plasma, thereby keeping the conjugates as a source of AZT in the circulatory system for prolonged period, these appear to be another group of prodrugs of AZT which may enhance the efficacy of AZT for AIDS treatment. However, their pharmacokinetic profile will eventually ascertain their real potential as a more efficaciousaiternative to AZT.
;!-;
Materials and Experimental procedures: chemistry
Melting points (uncorrected) were recorded using Mel-temp apparatus. Elemental analyses were periormed by Galbraith Laboratories, Inc. (Knoxville, TN) IR spectra were recorded on a Perkin-Elmer infrared spectrophotometer (Noywalk, C1). 1 H NMR spectra were recorded on a Bruker/IBM-SY200 Spectrometer (Bellerica, MA) at 270 MHz (Me4Si internal standard) and are expressed in ppm. Thin layer chromatography (fLC) was performed on precoated silica gel plastic sheets 60F 2s4 (0.2mm) EM Reagents. Compound visualization was effected with ultraviolet light (254nm). Silica gel 60 (7G-230 mesh ASTM) was used for column chromatography.
11{3-Hydroxy-3-oxoandrost-3-ene-17{3-carboxylic acid
To a solution of periodic acid (1.73g, 7.6 mmol) in H 20 (40ml) 
16-Cyano-11{3-hydroxy-3-oxoandrosta-1 ,4-diene-17{3carboxylic acid (2)
Methyl ester of acid 2 (369mg, 1 mmol) was dissolved in MeOH (30ml) and a NaOH solution (2N, 30ml) was added. After 6h, volume of the resultant mixture was reduced to 30 ml and the solution was cooled in an ice bath. The cooled solution was
To a mixture of prednisolone (1.44g, 4.0 mmol) and K 2COa (2.0g) in MeOH (100ml), air was passed for 10 min. After stirring the mixture for 16h, it was concentrated to reduce the volume to 20ml. The residual solution was diluted with water (200ml) and then extracted with EtOAC (3 x 50ml). The aqueous layer was cooled and acidified with 2 N HCI. The acidified aqueous layer was extracted with EtOAC (3 x 100ml). The organic layer was dried (Na2S04) and then concentrated. The precipitate was filtered and dried to afford 3 (1.1 g, 80%): mp 254-260°C (EtOAc-MeOH); IR (KBr) 1655cm-l (3-CO), 1730cm-1 (17-C0 2H 
3'-Azido-3'-deoxy-5'-O-[(11{3-hydroxy-3-0xo-17{3androst-4-enyljcarbonyl]thymidine (4)
DCC (60mg, 0.3 mmol) was added to a cooled and stirred mixture of 1 (48mg 0.15 mmol), AZT (27mg, 0.1 mmol) and DMAP (24mg, 2 mmol) in dry DMF (1ml). After 80h, the DMF was removed in vacuo and the residue was suspended in EtOAc (4ml). The suspension was applied to column of silica gel packed in hexane. Elution of the column (hexane -EtOAC) afforded 4 (49.4mg, 85%): mp 19G-191°C (EtOAc -hexane); IR (KBr) 1665cm-1 (3-CO), 1710cm-l (C0 2), 2080cm-l (-N a); 'H NMR (CDCla) 1.00 and 1.45 (2 x s, 2 x 3 H, CH a), 1.95 (s, 3 H, 5-CHa-AZ1), 4.05 to 4.45 (m, 5 H, H-3',4',5' and 11), 5.70 (s, 1 H, H-4), 6.05 (t, 1 H, J = 6.75Hz, H-1 '), 7.15 (s,1 H, H-6-AZ1).Anal. calcd. forCaoHagNs07: C, 61.96; H, 6.71; N, 12.04. Found: C, 61.80; H, 6.96; N, thymidine (5) Using the procedure described for the synthesis of 4, ester 5 was synthesized from acid 2 (36mg, 0. , 6.00; N, 13.90. Found: C, 61.61; H, 5.97; N, thymidine (6) A mixture of acid 3(1.75mg, 0.5 mmol) and COl (96mg, 0.6 mmol) was stirred in DMF (2.5ml) for 2 h. AZT (117mg, 0.43 mmol) and DMAP (63mg, 0.5 mmol) was then added to this solution. After 96 h, DMF was evaporated in vacuo the residue was left for 24 hat room temperature to solidify. The solid was suspended in MeOH (10ml) and refluxed for 30 min. The suspension was cooled and then the solid was filtered to afford 6 (230mg, 75%): mp 244-246°C (DMF -CHCl s); IR (KBr) 1655cm-1 (3-CO), , 6.35; N, 11.40. Found: C, 58.87; H, 6.71; N, 11.16 .
Materials and Experimental procedures: virology
Anti-HIVactivityevaluation
Compounds were dissolved in Me2S0 and then diluted 1:100 in cell culture medium before preparing serial half-log 1o dilution. T4-lymphocytes (CEM cell line)were added into wells of microtitre plates and after a brief interval HIV-1 was added, resulting in a 1:200 final dilution of the compound. Uninfected cells with the compound served as a toxicity control, and the infected and uninfected cells without the compound served as basic controls. Cultures were incubated at 37"C in 5% CO 2 atmosphere for 6 days and then the tetrazolium salt XTT was added to all wells, and the cultures were incubated to allow formazan colour developrnent by viable cells. Individual wells were analysed spectrophotometrically to quantitate formazan production, and in addition were viewed microscopically for detection of viable cells and confirmation of protective activity. Drug-treated virus-infected cells were compared with drug treated non cells and with other appropriate controls (untreated infected and untreated non-infected cells, drug-containing wells without cells, etc.) on the same plate. Data were reviewed in comparison with other tests done at the same time and a determination about the activity was made.
Evaluation of the stability of text compounds in cell culture medium
In 130 fLl of Me2S0 0.2 mmol of the test compound was dissolved and then diluted with 13 ml of cell culture medium. Half of this mixture was incubated for 6 days in CO 2 atmosphere at 37°C. The remainder was freeze dried and then the residue was suspended in HPLC grade MeOH (3ml). The suspension was vortexed and then filtered. The filtrate was analysed by HPLC (waters with fL bonda pak C18 column, 3.9 x 300 mm). A similarly incubated part was processed after six days and then analysed. EtOH-water was used as a mobile phase at flow rate of 0.2ml mln" and the UV detector was set at 267 nm wavelength and 0.001 aufs sensitivity.
